Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.43 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30906267 | 0.95 | CRBN (0.52) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL20231475 | 0.95 | CRBN (0.52) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL21759799 | 0.89 | CRBN (0.53) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL31748857 | 0.89 | CRBN (0.53) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL30942283 | 0.86 | IKZF2 (0.53) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL27302562 | 0.86 | IKZF2 (0.53) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL20442592 | 0.85 | IKZF2 (0.52) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL31025890 | 0.85 | IKZF2 (0.70) | IKZF2CRBNDDB1IKZF1 | |
| SCHEMBL29648391 | 0.85 | IKZF2 (0.52) | IKZF2CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL27302563 | 0.85 | IKZF2 (0.52) | IKZF2CRBNDDB1CSNK1A1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236607-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2025-07-24 | — | — | US | disclosed |
| EP-4499148-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192534-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236607-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | CDK9, CDK19, CDKL2 | IKZF2 500/4885CRBN 70/4885BTK 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.